Aquestive Therapeutics Files 8-K

TL;DR

AQST filed a routine 8-K, no major news.

AI Summary

Aquestive Therapeutics, Inc. filed an 8-K on October 24, 2024, reporting on other events and financial statements. The filing does not contain specific new material events or financial figures beyond standard reporting requirements.

Why It Matters

This 8-K filing indicates routine corporate reporting by Aquestive Therapeutics, Inc., without disclosing immediate material changes or significant financial updates.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain information that suggests an immediate change in risk for the company.

Key Players & Entities

• Aquestive Therapeutics, Inc. (company) — Registrant
• MonoSol Rx, Inc. (company) — Former company name
• October 24, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I

Filing Documents

• aqst-20241024.htm (8-K) — 30KB
• aquestivereportstoplined.htm (EX-99.1) — 16KB
• oassupplementarymaterial.htm (EX-99.2) — 23KB
• aquestivereportstoplined001.jpg (GRAPHIC) — 283KB
• aquestivereportstoplined002.jpg (GRAPHIC) — 281KB
• aquestivereportstoplined003.jpg (GRAPHIC) — 351KB
• aquestivereportstoplined004.jpg (GRAPHIC) — 196KB
• oassupplementarymaterial001.jpg (GRAPHIC) — 94KB
• oassupplementarymaterial002.jpg (GRAPHIC) — 299KB
• oassupplementarymaterial003.jpg (GRAPHIC) — 125KB
• oassupplementarymaterial004.jpg (GRAPHIC) — 99KB
• oassupplementarymaterial005.jpg (GRAPHIC) — 98KB
• oassupplementarymaterial006.jpg (GRAPHIC) — 115KB
• oassupplementarymaterial007.jpg (GRAPHIC) — 84KB
• oassupplementarymaterial008.jpg (GRAPHIC) — 87KB
• oassupplementarymaterial009.jpg (GRAPHIC) — 84KB
• oassupplementarymaterial010.jpg (GRAPHIC) — 110KB
• oassupplementarymaterial011.jpg (GRAPHIC) — 118KB
• oassupplementarymaterial012.jpg (GRAPHIC) — 117KB
• oassupplementarymaterial013.jpg (GRAPHIC) — 99KB
• oassupplementarymaterial014.jpg (GRAPHIC) — 98KB
• oassupplementarymaterial015.jpg (GRAPHIC) — 101KB
• oassupplementarymaterial016.jpg (GRAPHIC) — 91KB
• oassupplementarymaterial017.jpg (GRAPHIC) — 37KB
• 0001628280-24-043505.txt ( ) — 4298KB
• aqst-20241024.xsd (EX-101.SCH) — 2KB
• aqst-20241024_lab.xml (EX-101.LAB) — 21KB
• aqst-20241024_pre.xml (EX-101.PRE) — 12KB
• aqst-20241024_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure. On October 24, 2024, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing positive topline results from its oral allergy syndrome (OAS) challenge study for Anaphylm (epinephrine) Sublingual Film and posted on the Events and Presentations page within the Investor page on the Company's website located at www.aquestive.com information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later company filing or other means. Anaphylm has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the United States Food and Drug Administration (FDA). A copy of the Company's press release and investor presentation are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report and incorporated in this Item 7.01 by reference. The information in this Item 7.01 (including Exhibit 99.1 and 99.2) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

01

Item 8.01 Other Events. On October 24, 2024, the Company released positive topline results from its OAS challenge study for Anaphylm (epinephrine) Sublingual Film. Anaphylm has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the FDA.

Financial Statements and Exhibits

Financial Statements and Exhibits (d)Exhibits. Exhibit Number Description 99.1 Press Release, dated October 24, 2024. 99.2 Anaphylm (epinephrine) Sublingual Film Oral Allergy Syndrome Challenge Study Supplemental Materials, dated October 24, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 24, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR